 MELBOURNE, Australia, Oct. 19, 2021 GLOBE NEWSWIRE -- Opthea Limited ASX:OPT; Nasdaq:OPT, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced that the first clinical trial sites in the Asia-Pacific region are now open for patient enrollment into the OPT-302 Phase 3 pivotal clinical program for the treatment of wet neovascular age-related macular degeneration AMD. The clinical trial sites, located in Australia, further build upon the progress of other international regions including the U.S., Canada and Europe that are also actively recruiting patients. 